Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection

February 2010
American Journal of Health-System Pharmacy;2/1/2010, Vol. 67 Issue 3, p193
Academic Journal
Purpose. The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed. Summary. While single mutations confer resistance to earlier nonnucleoside reverse transcriptase inhibitors (NNRTIs), etravirine exhibited an increased barrier to resistance by requiring multiple mutations for resistance to occur in preclinical studies. Randomized controlled trials have demonstrated the efficacy of etravirine in achieving HIV RNA viral loads of <50 copies/ mL and a significant increase in baseline CD4+ lymphocyte count in treatment-experienced patients. There has been a trend toward increased rates of death, progression to acquired immunodeficiency syndrome, and opportunistic infections in patients using placebo during Phase III trials. Baseline patient characteristics that correlate with changes in etravirine efficacy are reported. Mild-to-moderate rash and nausea are the most common adverse effects of etravirine. If rash is suspected, etravirine should be discontinued and rechallenge should be avoided due to the risk of severe and possibly fatal skin reactions. Unlike some antiretrovirals, increased risks of hepatic, lipid, or neuropsychiatric abnormalities are not correlated with its use. Several drug interactions are expected with etravirine use, and some may require dosage adjustment or substitution of concurrent drugs. No dosage adjustments are recommended for patients with mild-to-moderate hepatic or renal impairment. Conclusion. Etravirine, a second-generation NNRTI, is efficacious in achieving viral suppression and improving the immune function in treatment-experienced HIV-infected patients.


Related Articles

  • Monitoring HIV-1 Resistance across the Globe.  // PLoS Medicine;Apr2005, Vol. 2 Issue 4, p270 

    Discusses research being done on the impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype. Reference to a study by Rami Kantor, D. A. Katzenstein, B. Efron, A. P. Carvalho, B. Wynhoven, et al. published in the same issue; Development of...

  • Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. de Mendoza, Carmen; Jiménez-Nacher, Inmaculada; Garrido, Carolina; Barreiro, Pablo; Poveda, Eva; Corral, Angélica; Zahonero, Natalia; González-Lahoz, Juan; Soriano, Vincent // Clinical Infectious Diseases;6/1/2008, Vol. 46 Issue 11, p1782 

    Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P <.001), despite elevated and stable...

  • The ''Connection'' Between HIV Drug Resistance and RNase H. Delviks-Frankenberry, Krista A.; Nikolenko, Galina N.; Pathak, Vinay K. // Viruses (1999-4915);Jul2010, Vol. 2 Issue 7, p1476 

    Currently, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are two classes of antiretroviral agents that are approved for treatment of HIV-1 infection. Since both NRTIs and NNRTIs target the polymerase (pol) domain of reverse...

  • Improved Interpretation of Genotypic Changes in the HIV-1 Reverse Transcriptase Coding Region That Determine the Virological Response to Didanosine. De Luca, Andrea; Di Giambenedetto, Simona; Trotta, Maria Paola; Colafigli, Manuela; Prosperi, Mattia; Ruiz, Lidia; Baxter, John; Clevenbergh, Philippe; Cauda, Roberto; Perno, Carlo-Federico; Antinori, Andrea // Journal of Infectious Diseases;12/1/2007, Vol. 196 Issue 11, p1645 

    Background. Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed. Methods. Baseline HIV-1 RT genotypes and 12-week virological outcomes for patients undergoing...

  • The Human Immunodeficiency Virus Type 1 Carboxyl-Terminal Third of Capsid Sequence in Gag-Pol Is Essential but Not Sufficient for Efficient Incorporation of Pr160 intoVirus Particles. Hsu-Chen Chiu; Wei-Hao Liao; Szu-Wen Chen; Chin-Tien Wang // Journal of Biomedical Science;May/Jun2004, Vol. 11 Issue 3, p398 

    To elucidate the role of the C-terminal portion of Gag in the incorporation of human immunodeficiency virus type 1 (HIV-1) Gag-Pol into virus particles, a series of HIV-1 Gag-Pol mutants with deletions in the C-terminal gag sequence was constructed and viral incorporation of the Gag-Pol deletion...

  • Nonintegrated Circular Forms of the HIV-1 Provirus DNA in Experimental HIV Infection. Gashnikova, N. M.; Plyasunova, O. A.; Mamaeva, O. A.; Fedyuk, N. V.; Pokrovskii, A. G. // Doklady Biochemistry & Biophysics;Mar/Apr2001, Vol. 377 Issue 1-6, p116 

    Discusses a research on nonintegrated circular forms of the HIV-1 provirus DNA in experimental HIV infection. Reproduction of HIV-1; Method for testing the circular proviral DNA forms; Feasibility of an alternative pathway of virus reproduction without involvement of reverse transcriptase.

  • Drug-Resistant HIV Infection among Drug-Naive Patients in Israel. Grossman, Z.; Lorber, M.; Maayan, S.; Bar-Yacov, N.; Levy, I.; Averbuch, D.; Istomin, V.; Chowers, M.; Sthoeger, Z.; Ram, D.; Rudich, H.; Mileguir, F.; Pavel, R.; Almaliach, R.; Schlaeffer, F.; Kra-Oz, Z.; Mendelson, E.; Schapiro, J. M.; Riesenberg, K. // Clinical Infectious Diseases;1/15/2005, Vol. 40 Issue 2, p294 

    Background. In Israel, <0.0 6% of the general population is infected with human immunodeficiency virus (HIV), with a much higher prevalence among specific groups. These groups are distinguished demographically by risk behavior category and by virus subtype. We investigated transmission of drug...

  • Evaluation of a Low Cost Reverse Transcriptase Assay for Plasma HIV-1 Viral Load Monitoring. Greengrass, Vicki L.; Turnbull, Shannon P.; Hocking, Jane; Dunne, Amanda L.; Tachedjian, Gilda; Corrigan, Gary E.; Crowe, Suzanne M. // Current HIV Research;Apr2005, Vol. 3 Issue 2, p183 

    We evaluated a low cost manual reverse transcriptase assay (ExaVir(ρ) Load V.1 and V.2; Cavidi Tech AB) against commercially available HIV RNA assays that quantify viral load to assess its suitability for use in resource-constrained settings. Frozen plasma samples previously tested for RNA by...

  • Study boosts role of NNRTI-based triple therapy as initial HIV treatment.  // Formulary;Feb2000, Vol. 35 Issue 2, p120 

    Focuses on the study which examines the role of nonnucleoside reverse transcriptase inhibitor-based triple therapy as initial HIV treatment. Regimens used for treatment in the trial study; Adverse effects of indinavir-based therapy on trial patients; Factors that cause the superior results from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics